pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy
Abstract Clinical efficacy of virotherapy is often limited by poor transduction and off-target effects. To overcome these hurdles, we engineered a multi-stage, pH-responsive virus-drug conjugate (VDC) for targeted, cancer immunotherapy. Our VDC comprises a recombinant adeno-associated virus serotype...
I tiakina i:
| Ngā kaituhi matua: | , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2026-03-01
|
| Rangatū: | Journal of Nanobiotechnology |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12951-026-04347-9 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|